

## Press release

### **New partnership gives Nestlé Health Science access to one of the world's leading Traditional Chinese Medicine libraries**

Lutry, Switzerland, 28 November 2012 - Nestlé Health Science, a fully owned subsidiary of Nestlé, and the pharmaceutical and healthcare group Chi-Med, have agreed to form a 50/50 joint venture to be named Nutrition Science Partners Limited (NSP).

NSP will research, develop, manufacture and market innovative nutritional and medicinal products derived from botanical plants.

The new partnership will give Nestlé Health Science access to one of the world's leading Traditional Chinese Medicine libraries. NSP will focus on gastrointestinal health and may in the future expand into the metabolic disease and brain health areas.

#### **Research and development**

The new partnership gives Nestlé Health Science access to Chi-Med's traditional Chinese medicine library of more than 50,000 extracts from over 1,200 different herbal plants and its world-class expertise. This includes the access to use the botanical research and development platform in gastrointestinal areas, which includes discovery research, non-clinical and pharmaceutical science functions and an understanding of the botanical guidelines and regulations.

#### **'Botanical-based nutrition' and value for patients**

"This joint venture provides Nestlé Health Science with an opportunity to develop and commercialise truly innovative and scientifically validated botanical-based nutrition for personalised healthcare in gastrointestinal health," said Luis Cantarell, President and Chief Executive Officer for Nestlé Health Science.

"Nestlé Health Science will bring unique competencies in nutritional sciences, diagnostics and commercial capabilities, and Chi-Med will provide its best-in-class traditional Chinese medicine library and discovery platform, which will be the basis of Nutrition Science Partners' future gastrointestinal pipeline."

"We are joined in this important endeavour by Nestlé Health Science, and are confident that by harnessing the resources of our two groups, we will succeed in bringing a stream of novel botanical medicines and nutritional products to market and in-so-doing build significant value for patients and for our shareholders," said Christian Hogg, Chief Executive Officer of Chi-Med.

#### **Supporting clinical trials**

Hutchison MediPharma Limited, a subsidiary of Chi-Med, is already advanced in the research and development into a first-of-its-kind botanical product, to be taken orally, to manage mild to moderate inflammatory bowel disease. Its main ingredient is extracted from 'andrographis paniculata', a herb used in Traditional Chinese Medicine. The new partnership will further support the product development during its next stage of clinical trials, which is scheduled to start in early 2013.

#### **Nestlé Health Science**

This latest investment by Nestlé Health Science will enhance its ability to develop science-based personalised nutritional solutions.

The company is active in the acute disease sectors of ageing medical care, critical care and surgery, and paediatric medical care. It is also developing new approaches to chronic diseases in the areas of gastrointestinal health, metabolic health and brain health.

### Elevating role of nutrition

The new partnership will build on Nestlé Health Science's ambition to explore personalised health care combining nutrition, drugs and diagnostics. This approach was made possible through the acquisition of leading **US gastrointestinal diagnostics company Prometheus** through its diagnostics and in-licensed specialty pharmaceuticals in gastroenterology and oncology, which helps the patient manage their condition from diagnostics to treatment.

The new joint venture is an opportunity for Nestlé Health Science to establish this approach for patients outside of the United States.

The company has made a number of investments to build on its gastrointestinal portfolio including a minority stake in New Zealand-based **Vital Foods** and the acquisition of **CM&D Pharma Ltd.** To expand its portfolio of clinical nutritional solutions for metabolic disorders, Nestlé Health Science acquired UK-based **VitaFlo**. And to boost its brain health portfolio, it acquired a stake in a **US firm Accera**.

### Terms of partnership

Nutrition Science Partners will be funded primarily through the initial Nestlé Health Science capital investment and further milestone payments linked to success of clinical and commercial activities.

This transaction is subject to regulatory approval.

###

### About Nestlé Health Science

Nestlé Health Science was formed in January 2011 to spearhead the development of science-based personalised nutritional solutions. Building on its core HealthCare Nutrition business, the company has ambitions to address chronic conditions in the area of Gastrointestinal Health, Metabolic Health and Brain Health. Nestlé Health Science offers nutritional solutions for people with specific dietary needs related to illnesses, disease states or the special challenges of different life stages. Nestlé Health Science, a wholly owned subsidiary of Nestlé SA, employs around 3,000 people worldwide and has its headquarters in Lutry, Switzerland. For more information, visit [www.nestlehealthscience.com](http://www.nestlehealthscience.com).

### About Chi-Med

Chi-Med is the holding company of a healthcare group based primarily in China and was listed on the Alternative Investment Market of the London Stock Exchange in May 2006 (AIM:HCM). It is focused on researching, developing, manufacturing and selling pharmaceuticals and health oriented consumer products. For more information, visit [www.chi-med.com](http://www.chi-med.com).

Chi-Med is majority owned by Hutchison Whampoa Limited, an international company listed on the Main Board of The Stock Exchange of Hong Kong Limited. Hutchison Whampoa employs over 250,000 people in 53 countries. For more information, visit [www.hutchison-whampoa.com](http://www.hutchison-whampoa.com).

### About Hutchison MediPharma Limited (HMP)

HMP is a subsidiary of Chi-Med and a novel drug R&D entity focusing on discovering, developing and commercialising innovative therapeutics in cancer and autoimmune diseases. With a team of around 200 scientists and staff, its pipeline comprises novel oral products for cancer and inflammation in development in North America, Europe, Australia and Greater China. For more information, visit [www.hmpglobal.com](http://www.hmpglobal.com).

#### Contacts:

<mailto:nestlehealthscience.external@nestle.com>

#### Analyst Call:

There will be a **conference call for analysts at 08:30 GMT (09:30 CET)** this morning, hosted by Luis Cantarell and Christian Hogg. Dial-in details are:

UK: 0808 109 0700 (Toll free)

International: +44 (0) 20 3003 2666

Participants need to please specify that they dial in for Chi-Med call.